COCP
Cocrystal Pharma Inc

16,106
Loading...
Loading...
News
all
press releases
Cocrystal Pharma (NASDAQ:COCP) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright restated their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP - Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $10.00 target...
Ticker Report·1y ago
News Placeholder
More News
News Placeholder
Cocrystal Pharma, Inc. (NASDAQ:COCP) to Post Q1 2025 Earnings of ($0.49) Per Share, HC Wainwright Forecasts
Cocrystal Pharma, Inc. (NASDAQ:COCP - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cocrystal Pharma in a research report...
Zolmax·1y ago
News Placeholder
Cocrystal Pharma GAAP EPS of -$1.87
Cocrystal Pharma GAAP EPS of -$1.87...
SeekingAlpha.com: All News·1y ago
News Placeholder
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips COCP stock results show that Cocrystal Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. The post COCP...
InvestorPlace·1y ago
News Placeholder
Recap: Cocrystal Pharma Q4 Earnings
read more...
Benzinga·1y ago
News Placeholder
Cocrystal Pharma sees cash runway beyond next 12 months
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Cocrystal Pharma reports 2023 EPS ($1.87), consensus ($2.09)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
FDA feedback following the Company's submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
Globe Newswire·2y ago
News Placeholder
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ( Cocrystal or...
Globe Newswire·2y ago
News Placeholder
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage...
Accesswire·2y ago

Latest COCP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.